Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
mRNA vaccines have emerged as a pivotal tool to respond to global pandemics like SARS-CoV-2. However, RNA vaccines face challenges with limited duration of immunogenicity and reliance on a special cold-chain for long term storage. Self-amplifying (saRNA) vaccines have shown sustained antigen expression and durable immune responses. Herein we developed lyophilization formulations for a SARS-CoV-2 saRNA ionizable lipid nanoparticle (LNP) to help reduce dependence on the cold chain. Our results show the induction of robust immune responses in mice by saRNA-LNPs when delivered either intramuscularly or intradermally following lyophilization and storage for up to 15 weeks at above freezing temperatures. Additionally, lyophilized saRNA-LNPs were efficiently delivered into the skin via microfluidic microarray patches (M-MAPs), inducing strong humoral and cellular immunity. M-MAPs offer a painless, self-administered alternative to traditional injections for transdermal drug delivery. Our work highlights the potential for a thermostable, self-administered RNA-LNP vaccine to improve vaccine coverage.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jconrel.2025.113944 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pulmonary delivery of small circular RNA vaccines for influenza prevention.
J Control Release
September 2025
Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA; Bioinnovations in Brain Cancer, Biointerfaces Institute; The Developmental Therapeutics Program, Rogel Cancer Center; Center for RNA Biomedicine, University of Michigan, Ann Arbor, MI 48109,
Lipid nanoparticles (LNPs) have played an instrumental role in the delivery of RNA therapeutics and vaccines, including the emerging class of synthetic circular RNA (circRNA). Pulmonary vaccines hold the potential to prevent various respiratory infectious diseases, such as influenza caused by influenza infection. Here, we report the pulmonary delivery of LNPs loaded with highly stable small circRNA vaccine for influenza prevention.
View Article and Find Full Text PDFEffect of Omicron BA.1-based compared to prototype booster mRNA vaccination on incidence of COVID-19 in the COVAIL trial.
Vaccine
September 2025
Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Background: Covid-19 vaccines are updated to match circulating strains based on reasoning that better strain-matched immunogenicity should provide better protection. Randomized evidence with disease endpoints to support strain matching is lacking. We evaluated COVID-19 incidence among adults randomized to a second booster of Prototype or Omicron-based vaccines.
View Article and Find Full Text PDFImmunology of RNA-based vaccines: the critical interplay between inflammation and expression.
Mol Ther
September 2025
Sanofi, Waltham, MA, USA.
Since its use during the COVID-19 pandemic, mRNA has emerged as a leading candidate vaccine platform for pandemic infections. A critical difference between RNA-encoded antigen and protein vaccines is that RNA-based vaccines require the antigen to be translated in the body, adding an important variable. Much of the research focus in the field has been on ways to increase expression, but inflammation plays a critical role.
View Article and Find Full Text PDFManipulating Zika virus RNA tertiary structure for developing tissue-specific attenuated vaccines.
EMBO Mol Med
September 2025
State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, 100071, Beijing, China.
Traditional live attenuated vaccines (LAVs) are typically developed through serial passaging or genetic engineering to introduce specific mutations or deletions. While viral RNA secondary or tertiary structures have been well-documented for their multiple functions, including binding with specific host proteins, their potential for LAV design remains largely unexplored. Herein, using Zika virus (ZIKV) as a model, we demonstrate that targeted disruption of the primary sequence or tertiary structure of a specific viral RNA element responsible for Musashi-1 (MSI1) binding leads to a tissue-specific attenuation phenotype in multiple animal models.
View Article and Find Full Text PDFDengue virus infection reprograms baseline innate immune gene expression.
Med
September 2025
Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore 169856, Singapore; Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore; Department of Clinical Translational Research, Singapore General Hospital, Singapo
Background: All three dengue vaccines that have completed phase 3 clinical trials have shown greater efficacy in dengue-seropositive compared to dengue-seronegative individuals. This includes the live-attenuated tetravalent dengue vaccine TAK-003, where immunogenicity in baseline seronegative individuals remains lower after two doses, despite seroconversion after the first dose, compared to baseline seropositive individuals after one dose.
Methods: A whole-genome microarray was used to analyze the host response to TAK-003.